首页> BMC cancer> Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

导出 OA

翻译打印收藏纠错

第一作者： Marc-Andrea,Baertsch

第一单位： Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

作者： Marc-Andrea,Baertsch ^[1] ; Jana,Schlenzka ^[1] ; Elias K,Mai ^[1] ; Maximilian,Merz ^[1] ; Jens,Hillengaß ^[1] ; Marc S,Raab ^[1] ; Dirk,Hose ^[1] ; Patrick,Wuchter ^[1] ; Anthony D,Ho ^[1] ; Anna,Jauch ^[2] ; Thomas,Hielscher ^[3] ; Christina,Kunz ^[3] ; Steffen,Luntz ^[4] ; Stefan,Klein ^[5] ; Ingo G H,Schmidt-Wolf ^[6] ; Martin,Goerner ^[7] ; Martin,Schmidt-Hieber ^[8] ; Peter,Reimer ^[9] ; Ullrich,Graeven ^[10] ; Roland,Fenk ^[11] ; Hans,Salwender ^[12] ; Christof,Scheid ^[13] ; Axel,Nogai ^[14] ; Mathias,Haenel ^[15] ; Hans W,Lindemann ^[16] ; Hans,Martin ^[17] ; Richard,Noppeney ^[18] ; Katja,Weisel ^[19] ; Hartmut,Goldschmidt ^[20]

作者单位： Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. ^[1] Institute for Human Genetics, University of Heidelberg, Heidelberg, Germany. ^[2] Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany. ^[3] Coordination Centre for Clinical Trials (KKS), University Hospital Heidelberg, Heidelberg, Germany. ^[4] Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany. ^[5] Center for Integrated Oncology, Med. Klinik und Poliklinik III, University Hospital Bonn, Bonn, Germany. ^[6] Hematology, Oncology and Palliative Care, Community Hospital Bielefeld, Bielefeld, Germany. ^[7] Hematology and Oncology, Helios-Hospital Berlin Buch, Berlin, Germany. ^[8] Hematology, Oncology and Stem Cell Transplantation, Evangelisches Krankenhaus Essen-Werden gGmbH, Essen, Germany. ^[9] Hematology, Oncology and Gastroenterology, Maria-Hilf-Krankenhaus, Mönchengladbach, Germany. ^[10] Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Duesseldorf, Germany. ^[11] Hematology, Oncology and Palliative Care, Asklepios Klinik Altona, Hamburg, Germany. ^[12] Department I of Internal Medicine, University of Cologne, Cologne, Germany. ^[13] Internal Medicine III, Charité Campus Benjamin Franklin, Berlin, Germany. ^[14] Hematology, Oncology and Stem Cell Transplantation, Klinikum Chemnitz GmbH, Chemnitz, Germany. ^[15] Hematology and Oncology, Kath. Krankenhaus Hagen gem. GmbH - St.-Marien-Hospital, Hagen, Germany. ^[16] Hematology and Oncology, Goethe University, Frankfurt, Germany. ^[17] Hematology, University Hospital Essen, Essen, Germany. ^[18] Hematology, Oncology and Immunology, University of Tuebingen, Tuebingen, Germany. ^[19] Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. Hartmut.Goldschmidt@med.uni-heidelberg.de.;National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany. Hartmut.Goldschmidt@med.uni-heidelberg.de. ^[20]

关键词 Autologous stem cell transplantation High-dose chemotherapy Lenalidomide Multiple myeloma Relapse Second-line treatment